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Hepatocellular carcinoma (HCC) is heterogeneous in pathogenesis, phenotype and biological 
behavior. Various histopathological features of HCC had been sporadically described, and with 
the identification of common molecular alterations of HCC and its genomic landscape over 
the last decade, morpho-molecular correlation of HCC has become possible. As a result, up to 
35% of HCCs can now be classified into histopathological variants, many of which have unique 
molecular characteristics. This review will provide an introduction to the variously described 
histopathological variants of HCC in the updated WHO Classification of Digestive System 
Tumors. (J Liver Cancer 2020;20:17-24)
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Hepatocellular carcinoma (HCC) is defined as a primary 
hepatic malignancy showing hepatocellular differentiation, 
and it accounts for 75-85% of primary liver cancers.1 HCCs 
mostly arise in a background of chronic liver disease, the 
most common etiologies being hepatitis B, hepatitis C, 
chronic alcohol abuse, non-alcoholic fatty liver disease, in-
herited diseases (e.g. hemochromatosis and glycogen storage 
disease), and exogenous substances, such as aflatoxin B1.1,2 A 
minority of HCCs develop in a background of normal or 
near-normal liver, the most common setting being HCCs 
arising in hepatocellular adenomas.1,3,4 
Histologically, conventional HCCs demonstrate hepato-
cytic differentiation (i.e., the tumor cells resemble the ap-
pearance of hepatocytes with varying degrees of cyto-archi-
tectural atypia). The typical HCC tumor cells are cuboidal in 
shape, contain abundant eosinophilic cytoplasm with cen-
trally located nuclei, and are frequently arranged in a trabec-
ular pattern of variable thickness that at least vaguely recapit-
ulates the trabecular architecture of the normal hepatic 
acinus, with very little intratumoral stroma (Fig. 1).5 Howev-
er, many cases demonstrate deviations from this pattern; for 
example, some HCCs are predominantly composed of tumor 
cells with clear cytoplasm, some may show a predominantly 
pseudoglandular architecture and some may show abundant 
intratumoral fibrous stroma.
The 4th Edition of the World Health Organization 
(WHO) Classification of Digestive System Tumors (2010) 
described the histopathological features of HCC in detail, in-
cluding detailed descriptions of “cytological variants”, such 
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as pleomorphic cells, clear cells and spindle cells.6 In addi-
tion, a few “special types” of HCC were recognized, includ-
ing fibrolamellar carcinoma, scirrhous HCC, undifferentiat-
ed carcinoma, lymphoepithelioma-like carcinoma and 
sarcomatoid HCC. At that time, these special types were 
based mostly on the morphological features of the tumor. 
Since then, numerous large-scale genomic analyses in the 
recent years have clarified the mutational landscape and 
identified key cell-signaling and metabolic pathways related 
to hepatocarcinogenesis.7-10 This has resulted in a large num-
ber of molecular subclasses and signatures of HCC, and has 
highlighted the heterogeneity of HCC, in pathogenesis, phe-
notype and biological behavior. Recent studies have provided 
increasing evidence for morpho-molecular correlation of 
HCCs, and these efforts have resulted in several proposed 
histopathological variants of HCC.11 As many as 35% of 
HCCs can now be classified into histopathological variants, 
which have been introduced in the latest WHO Classification 
of Digestive System Tumors, 5th Edition1 and the distinction 
between most of these variants is now supported by the mo-
lecular features of the tumors (Table 1). In this review, we 
will summarize the recently described histopathological vari-
ants of HCCs. 
STEATOHEPATITIC VARIANT
The steatohepatitic variant of HCC, or steatohepatitic 
HCC, demonstrates the histological features of steatohepati-
tis within the tumor, including steatosis, ballooning of tumor 
cells, inflammation and the typical “chicken-wire pattern” 
pericellular fibrosis (Fig. 2).11-14 It accounts for 5-20% of 
HCCs, and the background liver may show steatohepati-
tis.13,14 Although this variant has been shown to be less often 
associated with vascular invasion or satellite nodules, its 
prognosis seems to be similar to conventional HCCs so far.11 
The key molecular features include IL-6/JAK/STAT activa-
tion, and lower frequency of CTNNB1 , TERT , and TP53  
mutations compared to other HCCs.11
CLEAR CELL VARIANT
In the clear cell variant of HCC, the majority (>80%) of 
tumor cells demonstrate clear cytoplasm (Fig. 3).15 The clear 
cytoplasm is a result of glycogen accumulation, although it is 
sometimes hard to discriminate from lipid droplets that are 
intermixed; in this regard, some degree of steatosis is accept-
able for a diagnosis of clear cell HCC. About 3-7% of HCCs 
show this morphology, and although the prognosis has been 
Figure 1. Hepatocellular carcinoma, conventional. (A) An expanding nodular tumor with a slightly bulging cut surface is seen. The tumor is 
slightly bile-tinged with small foci of hemorrhage. (B) Microscopic examination of a typical hepatocellular carcinoma shows tumor cells with 
eosinophilic cytoplasm arranged in a trabecular pattern (hematoxylin-eosin stain, ×200). 
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shown to be better compared to conventional HCCs, there is 
still a lack of information on the clinical correlates or the 
molecular features of these tumors. Of note, it is important 
to discriminate clear cell HCC from metastatic clear cell renal 
cell carcinoma, as the morphology may be remarkably simi-
lar. Therefore, on encountering such cases in a biopsy, it is 
Table 1. Summary of the clinical, histopathological and molecular features of the hepatocellular carcinoma variants according to the 5th Edition 
of WHO Classification of Digestive System Tumors
Variant Histopathological features Molecular features Clinical features and prognosis
Steatohepatitic Tumor cells show histological 
features of steatohepatitis
IL-6/JAK/STAT activation
Lower frequency of CTNNB1, 
TERT and TP53 mutations
NAFLD may be present
Prognosis similar to conventional HCC
Clear cell Tumor cells show clear cytoplasm, 
due to glycogen accumulation




Prominent thick trabeculae  
(6-10 cells in thickness), frequent 
vascular invasion
Frequent TP53 mutation and 
FGF19 amplification
Poor prognosis, high serum AFP levels
Scirrhous Abundant intratumoral fibrous 
stroma (30-50% of the tumor), 
frequent expression of stemness-
related markers
Frequent TSC1/TSC2 mutations, 
TGF-β signaling activation
Clinical outcome still controversial; larger 
tumors have been associated with aggressive 
outcome compared to conventional HCC
Imaging findings often overlap with 
cholangiocarcinoma
Chromophobe Clear cytoplasm, focal areas of 
nuclear atypia (abrupt anaplasia)
ALT phenotype Prognosis similar to conventional HCC
Fibrolamellar HCC Large eosinophilic tumor cells 
arranged in parallel arrays with 
dense fibrous stroma
DNAJB1-PRKACA gene fusion Children and young adults; absence of 
underlying chronic liver disease; more 
frequent in Western countries
Better prognosis compared to conventional 
HCCs in cirrhotic livers; similar prognosis to 
HCCs in non-cirrhotic livers
Neutrophil-rich Diffuse intratumoral neutrophilic 
infiltration
G-CSF production by tumor Elevated blood leukocyte counts, C-reactive 
protein and IL-6
Poor prognosis compared to conventional HCC
Lymphocyte-rich Massive intratumoral lymphocytic 
infiltration, frequent PD-L1 
expression
Not known, not EBV-related Favorable clinical outcome compared to 
conventional HCC
WHO, World Health Organization; IL, interleukin; JAK, janus kinase; STAT, signal transducer and activator of transcription; NAFLD, non-alcoholic 
fatty liver disease; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; TGF-β, transforming growth factor-beta; ALT, alternative lengthening of 
telomere; G-CSF, granulocyte colony stimulating factor; PD-L1, programmed death-ligand 1; EBV, Epstein-Barr virus.
Figure 2. Hepatocellular carcinoma, steatohepatitic variant. (A) The tumor shows a yellowish hue on gross examination due to the lipid content. 
(B) At low power magnification, there is extensive intratumoral steatosis (right, hematoxylin-eosin stain, ×12.5). (C) Higher power magnification 
demonstrates the histological features of steatohepatitis, including steatosis, hepatocyte ballooning and Mallory-Denk bodies (hematoxylin-
eosin stain, ×100). (D) The perisinusoidal “chicken-wire pattern” fibrosis is highlighted by Masson’s trichrome stain (×100).
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advisable to check the patient’s clinicoradiological informa-
tion, and to consider performing immunohistochemical 
stains (e.g., PAX-8, CD10, RCC for renal cell carcinoma, and 
hepatocellular differentiation markers such as HepPar-1 and 
arginase-1 for HCC) to avoid this diagnostic pitfall.16
MACROTRABECULAR-MASSIVE VARIANT
The macrotrabecular-massive variant of HCC demon-
strates a characteristic microscopic appearance: prominent 
thick trabeculae, measuring more than 6-10 cells in thick-
ness, in at least 50% of the tumor (Fig. 4).1,11,17 The relative 
Figure 3. Hepatocellular carcinoma, clear cell variant. (A) Gross feature of the tumor. (B) The tumor (upper left) appears lighter compared to the 
adjacent hepatic parenchyma at low power (hematoxylin-eosin stain, ×12.5). (C) Most of the tumor cells show clear cytoplasm, due to 
intracytoplasmic glycogen accumulation (hematoxylin-eosin stain, ×200).
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Figure 4. Hepatocellular carcinoma, macrotrabecular massive variant. (A) Gross feature of the tumor. (B) At low power magnification, thick tumor 




 Haeryoung Kim, et al.
Histopathological variants of HCC
https://www.e-jlc.org/
frequency of this variant has been described to be about 5% 
in the WHO classification, although some have reported fre-
quencies of up to 20%, probably as a result of the varying 
histological criteria; the trabecular thickness criteria for mac-
rotrabecular-massive HCC has varied from 6 to 20 cells thick 
in the literature. From the molecular level, this variant is 
characterized by frequent TP53  mutation and FGF19  ampli-
fication.11,17 Macrotrabecular-massive HCCs have also been 
associated with frequent HBV infection, frequent vascular 
invasion, poor differentiation, CK19 expression, high serum 
AFP levels and a poor clinical outcome.11,17 
SCIRRHOUS VARIANT
Scirrhous HCC is characterized by dense intratumoral fi-
brous stroma, occupying at least 30-50% of the tumor 
(Fig. 5).11,18-20 The tumor cell nests are predominantly com-
posed of mature hepatocyte-like cells and rimmed by smaller 
tumor cells that resemble hepatic stem/progenitor cells – the 
latter population frequently express stemness-related mark-
ers, such as CK19, CK7, and epithelial cell adhesion mole-
cule.19,20 This variant accounts for 4% of HCCs, and the 
dense fibrous stroma results in imaging findings that overlap 
with those of cholangiocarcinoma. TSC1/TSC2  mutations 
and transforming growth factor-beta signaling activation 
have been demonstrated in these tumors.11,20 The clinical 
outcome of this variant is still controversial. However, scir-
rhous HCCs have been reported to demonstrate decreased 
survival compared to conventional HCCs, especially in larger 
tumors (≥5 cm), and aggressive pathological features (e.g. 
vascular invasion, infiltrative growth) have been more fre-
quently seen in these tumors compared to conventional 
HCCs.20,21
CHROMOPHOBE VARIANT
This is a rare (up to 3%) variant of HCC that is character-
ized by clear (chromophobic) cytoplasm of the tumor cells, 
and focal areas of striking nuclear atypia in a background of 
otherwise “bland-looking” cytology, and thus have been ini-
tially named “chromophobe HCC with abrupt anaplasia”.22 
From a molecular viewpoint, it is interesting that the majori-
ty of the reported cases demonstrated alternative lengthening 
of telomere phenotype by telomere fluorescence in situ hy-
bridization (FISH).22 Little is known regarding the clinical 
correlates of this variant, and the prognosis so far seems to be 
similar to conventional HCCs.
Figure 5. Hepatocellular carcinoma, scirrhous variant. (A) Gross feature of the tumor. (B) Dense intratumoral fibrosis is seen at low power 
magnification (hematoxylin-eosin stain, ×12.5). (C) The tumor cell nests are separated by the thick fibrous stroma (hematoxylin-eosin stain, ×100).
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FIBROLAMELLAR HCC (FIBROLAMELLAR 
CARCINOMA) 
The fibrolamellar subtype of HCC had already been desig-
nated as a subtype of HCC in the previous WHO classifica-
tion,6 and has unique clinical characteristics, including the 
age distribution (children and young adults) and the absence 
of underlying chronic liver disease.1,23 It is a rare subtype that 
accounts for up to 1% of HCCs and occurs more frequently 
in Western countries.1 Histologically, it is characterized by 
parallel arrays of large eosinophilic tumour cells with large 
vesicular nuclei and prominent nucleoli, and separated by 
dense fibrous septa. Due to the abundance of fibrous intratu-
moral stroma, it may appear similar to scirrhous HCC; how-
ever, the fibrous stroma of scirrhous HCC has been recently 
shown to contain more abundant cancer-associated fibro-
blasts and tumor-associated macrophages, and stemness-re-
lated marker expression is more frequently seen in scirrhous 
HCCs.24 Recently, DNAJB1-PRKACA  gene fusion has been 
demonstrated in fibrolamellar HCC, and hence FISH for 
PRKACA  gene rearrangement has been proposed to be a 
good diagnostic tool for this tumor.25,26 The prognosis of fi-
brolamellar HCC has been shown to be better than for con-
ventional HCCs that arise in cirrhotic livers, but similar to 
HCCs in non-cirrhotic livers.27 In addition, conventional 
HCCs with features of fibrolamellar HCC in parts of the tu-
mor have been shown to have similar prognosis with con-
ventional HCCs, suggesting that a strict criterion (fibrola-
mellar features in the entire tumor) is required for a 
diagnosis of fibrolamellar HCC.28
NEUTROPHIL-RICH VARIANT
This is a very rare variant of HCCs (less than 1%) that is 
characterized histologically by diffuse neutrophilic infiltra-
tion within the HCC, and clinically by elevated leukocyte 
counts, C-reactive protein and IL-6, and a poor prognosis 
compared to conventional HCCs. The tumor cells may have 
focal sarcomatoid appearance, and granulocyte colony-stim-
ulating factor production by the tumor cells have been re-
ported.29
LYMPHOCYTE-RICH VARIANT
The lymphocyte-rich variant of HCC has been shown to 
account for <1% of HCCs, and demonstrates massive intra-
Figure 6. Hepatocellular carcinoma, lymphocyte-rich variant. (A) Gross appearance of the tumor. (B) At low power magnification, the tumor is 
massively infiltrated by lymphocytes (hematoxylin-eosin stain, ×40). (C) The tumor cell trabeculae or nests are separated by dense lymphoid cell 
infiltrates (hematoxylin-eosin stain, ×100).
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tumoral lymphocytic infiltration (Fig. 6). It has also been re-
ferred to as lymphoepithelioma-like HCCs.29,30 These tumors 
have been associated with a favorable clinical outcome and 
also more frequent programmed death-ligand 1 expres-
sion.31-33 The molecular features of this subtype have not 
been characterized yet; however, an association with Epstein-
Barr virus infection has not been demonstrated, unlike simi-
lar tumors of some other organs such as the stomach.32 Inter-
estingly, a minority of HCCs also demonstrates lymphoid 
aggregates or follicles within the tumor, and the presence of 
these tertiary lymphoid structures has been associated with a 
favorable prognosis.34
CONCLUSION
Following the accumulation of clinicopathological studies 
on various histopathological forms of HCC and the increas-
ing number of molecular studies addressing the heterogene-
ity of HCC, there have been efforts to connect the histomor-
phological and molecular features of HCCs, and such links 
have resulted in the currently proposed HCC variants of the 
recent WHO Classification of Digestive System Tumors.1 
With the recent morpho-molecular correlations of HCCs 
and the identification of various histopathological variants of 
HCC, most of which are based on their molecular features, 
we can now not only better understand the pathogenesis of 
HCC, but also use this knowledge to predict patient outcome 
and to facilitate the development of targeted therapy. More 
importantly, the identification of histopathological variants 
of HCCs suggests that histopathology still has an important 
role in HCC patient management. 
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